Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/23072Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Gazi, I. F. | en |
| dc.contributor.author | Tsimihodimos, V. | en |
| dc.contributor.author | Tselepis, A. D. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.contributor.author | Mikhailidis, D. P. | en |
| dc.date.accessioned | 2015-11-24T19:30:20Z | - |
| dc.date.available | 2015-11-24T19:30:20Z | - |
| dc.identifier.issn | 1744-7682 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/23072 | - |
| dc.rights | Default Licence | - |
| dc.subject | Animals | en |
| dc.subject | Cardiovascular Diseases/*blood/*drug therapy | en |
| dc.subject | Cholesterol, LDL/*blood | en |
| dc.subject | Cholesterol, VLDL/blood | en |
| dc.subject | Humans | en |
| dc.subject | Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use | en |
| dc.subject | Hypoglycemic Agents/therapeutic use | en |
| dc.subject | Particle Size | en |
| dc.subject | Risk Factors | en |
| dc.title | Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1517/14712598.7.1.53 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/17150019 | - |
| heal.identifier.secondary | http://informahealthcare.com/doi/abs/10.1517/14712598.7.1.53 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2007 | - |
| heal.abstract | The National Cholesterol Education Programme Adult Treatment Panel III accepted the predominance of small dense low-density lipoprotein (sdLDL) as an emerging cardiovascular disease (CVD) risk factor. Most studies suggest that measuring low-density lipoprotein (LDL) particle size, sdLDL cholesterol content and LDL particle number provides additional assessment of CVD risk. Therapeutic modulation of small LDL size, number and distribution may decrease CVD risk; however, no definitive causal relationship is established, probably due to the close association between sdLDL and triglycerides and other risk factors (e.g., high-density lipoprotein, insulin resistance and diabetes). This review addresses the formation and measurement of sdLDL, as well as the relationship between sdLDL particles and CVD. The effect of hypolipidaemic (statins, fibrates and ezetimibe) and hypoglycaemic (glitazones) agents on LDL size and distribution is also discussed. | en |
| heal.journalName | Expert Opin Biol Ther | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
